Table 2.
Demographic and Baseline Characteristics by Species (M. abscessus/MAC only)
| Characteristic | Overall (n=30) | M. abscessus (n=13) | MAC (n=17) |
|---|---|---|---|
| Age (y) at NTM dx | 47.0 (12.1 to 91.3) | 29.6 (12.5 to 91.3) | 47.1 (12.1 to 77.1) |
| Age (y) at CFZ initiation | 54.1 (15.8 to 91.5) | 30.8 (16.3 to 91.5) | 56.8 (15.8 to 77.4) |
| Time (y) to CFZ initiation from NTM dx | 3.6 (0.2 to 21.6) | 1.7 (0.2 to 11.3) | 3.7 (0.3 to 21.6) |
| BMI (kg/m2)* (n=26) | 19.7 (13.5 to 28.5) | 22.0 (17.9 to 28.5) | 19.3 (13.5 to 26.8) |
| Female | 20 (67) | 8 (62) | 12 (71) |
| History of lung disease | 23 (77) | 10 (77) | 13 (76) |
| Cystic fibrosis | 8 (27) | 5 (38) | 3 (18) |
| Asthma | 7 (23) | 4 (31) | 3 (18) |
| COPD | 6 (20) | 0 (0) | 6 (35) |
| Other^ | 12 (40) | 5 (38) | 7 (41) |
| Former or current smoker* (n=25) | 10 (40) | 2 (20) | 8 (53) |
| Immunocompromised Status** | 10 (33) | 4 (31) | 6 (35) |
| Effectively Treated | 15 (50) | 9 (69) | 6 (35) |
| Site of infection | |||
| Bone | 1 (3) | 1 (8) | 0 (0) |
| Disseminated | 3 (10) | 1 (8) | 2 (12) |
| Lung | 26 (87) | 11 (85) | 15 (88) |
| Cough | 21 (70) | 11 (85) | 10 (59) |
| Fatigue | 5 (17) | 1 (8) | 4 (24) |
| Fever | 1 (3) | 0 (0) | 1 (6) |
| Hemoptysis | 2 (7) | 1 (8) | 1 (6) |
| Pain | 2 (7) | 2 (15) | 0 (0) |
| Phlegm | 17 (57) | 6 (46) | 11 (65) |
| Bronchiectasis* (n=27) | 14 (52) | 9 (75) | 5 (33) |
| Cavitary lesion* (n=27) | 8 (30) | 4 (33) | 4 (27) |
| Nodules* (n=26) | 18 (69) | 8 (73) | 10 (67) |
Values are median (range) or n (%).
*
Incomplete data resulted in a lower n
^
Other lung diseases include pneumothorax, interstitial lung disease, ciliary dyskinesia, and alpha-1 antitrypsin deficiency
**
Immunocompromised status include active cancer/chemotherapy, multiple sclerosis, prednisone >20 mg/d, primary biliary cholangitis, CVID, IgG monoclonal gammopathy, and use of etanercept, methotrexate, and/or certolizumab